Displaying 1 - 11 of 11
| Active Ingredient | METFORMIN |
| Therapeutic Class | BIGUANIDES |
| Indications |
Diabetes mellitus in obese, mature onset, diabetes without ketosis, when diet and attempts at weight loss fail. |
| Caution |
Anorexia or dyspep sia occurs in 15% of cases. Lactic acidosis is an infrequent side effect. Nausea, vomiting, diarrhoea, flatulence. C.f. Prescribing in liver and renal disease p. 15; 32. Not recom More ... |
| Dose Range |
500mg 2-3 times daily or 850mg once or twice daily with or after meals. Gradually increase at intervals of at least 1 week, to 2- 3 g daily . Doses greater than 2g, give in 3 divided doses. Extended Release: Initial dose of 500 mg once daily in |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN XR |
| Therapeutic Class | BIGUANIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN XR | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | SAXAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | VILDAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SITAGLIPTIN | METFORMIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VILDAGLIPTIN | METFORMIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic cont More ... |
| Caution | Asthenia, dizziness, headache, nausea;, peripheral oedema, tremor. |
| Dose Range | 1 tablet twice daily based on patient’s current metformin dose. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | Metformin/Empagliflozin |
| Therapeutic Class | Sodium Glucose Co-Transporter Inhibitor |
| Indications |
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. Empagliflozin, when used in combination with metformin, is also ind More ... |
| Caution | Urinary tract infection ,Decreased vitamin B12 levels; Female genital mycotic infections ;Increased urination ;Male genital mycotic infections; Necrotizing fasciitis of the perineum (Fournier’s gangre More ... |
| Dose Range |
Empagliflozin total daily dose: 10 mg For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | DAPAGLIFLOZIN | METFORMIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. |
| Caution | Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increas More ... |
| Dose Range | The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMPAGLIFLOZIN|METFORMIN |
| Therapeutic Class | SODIUM GLUCOSE CO TRANSPORTER INHIBITOR |
| Indications | Indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate |
| Caution | Lactic acidosis is a metabolic complication that can occur due to metformin accumulation during treatment and is fatal in ~50% of cases. Necrotizing fasciitis of the perineum (Fournier gangrene) repor More ... |
| Dose Range |
Take twice daily with meals (ie, divide total daily dose into 2 doses/day) For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin. |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |